Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of D-0120 in healthy volunteers
NCT03291782Phase 1Completed
- Sponsor
- InventisBio
- Start
- Sep 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of darbinurad in gout (5 arms), sponsored by InventisBio. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 2 weeks. Started Sep 2017; status: completed.
02
Drugs
darbinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT03291782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03291782.